Akcie v oběhu společnosti ProMIS Neurosciences
Jaká je hodnota metriky Akcie v oběhu společnosti ProMIS Neurosciences?
Hodnota metriky Akcie v oběhu společnosti ProMIS Neurosciences, Inc. je 6.750M 1.56%
Jaká je definice metriky Akcie v oběhu?
Akce v oběhu (Shares float) je podíl akcií společnosti vlastněných veřejnými investory vůči zablokovaným akcím (nejsou volně v oběhu).
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Akcie v oběhu společností v sektoru Health Care sektor na TSX ve srovnání se společností ProMIS Neurosciences
Čemu se věnuje společnost ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou akcie v oběhu podobnou společnosti ProMIS Neurosciences
- Hodnota metriky Akcie v oběhu společnosti BioVie je 6.734M 26.97%
- Hodnota metriky Akcie v oběhu společnosti BioVie je 6.734M 26.97%
- Hodnota metriky Akcie v oběhu společnosti BioVie je 6.734M 26.97%
- Hodnota metriky Akcie v oběhu společnosti u-blox AG je 6.739M 96.45%
- Hodnota metriky Akcie v oběhu společnosti Jerrick Media je 6.739M 66.65%
- Hodnota metriky Akcie v oběhu společnosti Sanco Industries je 6.748M 65.62%
- Hodnota metriky Akcie v oběhu společnosti ProMIS Neurosciences je 6.750M 1.56%
- Hodnota metriky Akcie v oběhu společnosti Lux Industries je 6.754M 22.46%
- Hodnota metriky Akcie v oběhu společnosti INEOS Styrolution India je 6.769M 38.49%
- Hodnota metriky Akcie v oběhu společnosti Emmbi Industries je 6.769M 38.27%
- Hodnota metriky Akcie v oběhu společnosti VerifyMe je 6.779M 92.89%
- Hodnota metriky Akcie v oběhu společnosti Cineline India je 6.783M 24.22%
- Hodnota metriky Akcie v oběhu společnosti Creative Eye je 6.783M 33.82%